A two-drug combination for treating advanced kidney cancer has shown sustained and durable clinical benefit in more than five years of follow-up, according to a study published in Nature Medicine. The ...
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial ...
A phase II randomized trial of nano-crystalline megestrol acetate for nutritional improvement in postoperative head and neck squamous cell carcinoma undergoing radiotherapy. This is an ASCO Meeting ...
Clinical and Molecular Characteristics of High-Risk, Recurrent, or Metastatic Endometrial Cancer That Is Human Epidermal Growth Factor Receptor 2–Low In this multicenter phase I trial, we enrolled ...
A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body's immune system to target and eliminate cancer cells appeared to reduce the ...
Pembrolizumab (Keytruda) given before and after surgery to supplement adjuvant therapy improved responses and survival in patients with previously untreated, locally advanced head and neck squamous ...
Previously, immature overall survival results of the NRG Oncology GY018 (NRG-GY018) trial suggested that the use of the immunotherapy drug pembrolizumab in combination with chemotherapy improved ...
Pembrolizumab demonstrated clinical activity in patients with mycosis fungoides (MF) and Sézary syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma (CTCL), with nearly half of treated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results